Gladstone Institutional Advisory LLC Sells 252 Shares of Illumina, Inc. (NASDAQ:ILMN)

Gladstone Institutional Advisory LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,591 shares of the life sciences company’s stock after selling 252 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Illumina were worth $480,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bleakley Financial Group LLC purchased a new position in Illumina in the 4th quarter worth approximately $751,000. Zacks Investment Management bought a new stake in shares of Illumina in the 3rd quarter worth $2,924,000. Freemont Management S.A. purchased a new position in shares of Illumina in the third quarter worth $1,565,000. Assenagon Asset Management S.A. lifted its holdings in shares of Illumina by 5.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock valued at $5,712,000 after purchasing an additional 2,338 shares in the last quarter. Finally, CCLA Investment Management boosted its position in shares of Illumina by 20.5% during the fourth quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock valued at $71,493,000 after buying an additional 91,122 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Down 1.5 %

NASDAQ ILMN opened at $100.24 on Friday. Illumina, Inc. has a 12 month low of $99.35 and a 12 month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. The stock’s 50 day moving average is $133.56 and its 200 day moving average is $134.88.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Research analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research analyst reports. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and lowered their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Barclays cut Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $130.00 to $100.00 in a report on Monday, February 10th. Finally, Canaccord Genuity Group cut their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.